Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Assets: 2016-2024

Historic Current Assets for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $276.1 million.

  • UroGen Pharma's Current Assets fell 42.88% to $168.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.5 million, marking a year-over-year decrease of 42.88%. This contributed to the annual value of $276.1 million for FY2024, which is 63.21% up from last year.
  • Per UroGen Pharma's latest filing, its Current Assets stood at $276.1 million for FY2024, which was up 63.21% from $169.2 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Current Assets registered a high of $276.1 million during FY2024, and its lowest value of $114.4 million during FY2021.
  • In the last 3 years, UroGen Pharma's Current Assets had a median value of $169.2 million in 2023 and averaged $191.4 million.
  • In the last 5 years, UroGen Pharma's Current Assets fell by 22.21% in 2020 and then spiked by 63.21% in 2024.
  • UroGen Pharma's Current Assets (Yearly) stood at $115.6 million in 2020, then dropped by 1.06% to $114.4 million in 2021, then rose by 12.69% to $128.9 million in 2022, then surged by 31.25% to $169.2 million in 2023, then spiked by 63.21% to $276.1 million in 2024.